Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor

Y Zhao, AA Adjei - The oncologist, 2015 - academic.oup.com
Angiogenesis, or the formation of new capillary blood vessels, occurs primarily during
human development and reproduction; however, aberrant regulation of angiogenesis is also …

The pancreas cancer microenvironment

C Feig, A Gopinathan, A Neesse, DS Chan, N Cook… - Clinical cancer …, 2012 - AACR
Pancreatic ductal adenocarcinoma (PDA) is a common and lethal malignancy resulting in
more than 250,000 deaths per year worldwide. Despite extensive efforts, cytotoxic and …

Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer

MA Jacobetz, DS Chan, A Neesse, TE Bapiro, N Cook… - Gut, 2013 - gut.bmj.com
Objective Pancreatic ductal adenocarcinoma (PDA) is characterised by stromal desmoplasia
and vascular dysfunction, which critically impair drug delivery. This study examines the role …

[HTML][HTML] Tumor microenvironment in chemoresistance, metastasis and immunotherapy of pancreatic cancer

S Wang, Y Li, C Xing, C Ding, H Zhang… - American journal of …, 2020 - ncbi.nlm.nih.gov
Pancreatic cancer (PC) is a fatal disease with high malignancy and difficult for early
diagnosis. PC causes more than 400,000 patient deaths world widely and becomes the …

CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer

A Neesse, KK Frese, TE Bapiro… - Proceedings of the …, 2013 - National Acad Sciences
Pancreatic ductal adenocarcinoma (PDA) is characterized by abundant desmoplasia and
poor tissue perfusion. These features are proposed to limit the access of therapies to …

Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer

PP Provenzano, SR Hingorani - British journal of cancer, 2013 - nature.com
Pancreatic ductal adenocarcinomas (PDAs) are notoriously aggressive and resistant to
treatment. They distinguish themselves further by their robust fibroinflammatory, or …

Signal transducer and activator of transcription 3, mediated remodeling of the tumor microenvironment results in enhanced tumor drug delivery in a mouse model of …

NS Nagathihalli, JA Castellanos, C Shi, Y Beesetty… - Gastroenterology, 2015 - Elsevier
Background & Aims A hallmark of pancreatic ductal adenocarcinoma (PDAC) is the
presence of a dense desmoplastic reaction (stroma) that impedes drug delivery to the tumor …

Probiotic spore-based oral drug delivery system for enhancing pancreatic cancer chemotherapy by gut–pancreas-axis-guided delivery

ZY Han, QW Chen, ZJ Fu, SX Cheng, XZ Zhang - Nano Letters, 2022 - ACS Publications
The chemotherapeutic effectiveness of pancreatic ductal adenocarcinoma (PDAC) is
severely hampered by insufficient intratumoral delivery of antitumor drugs. Here, we …

Microenvironment in determining chemo-resistance in pancreatic cancer: Neighborhood matters

P Dauer, A Nomura, A Saluja, S Banerjee - Pancreatology, 2017 - Elsevier
Abstract Every year, nearly 300,000 people are diagnosed with pancreatic cancer
worldwide, and an equivalent number succumb to this disease. One of the major challenges …

Pancreatic neuroendocrine tumors: molecular mechanisms and therapeutic targets

CK Maharjan, PH Ear, CG Tran, JR Howe… - Cancers, 2021 - mdpi.com
Simple Summary Pancreatic neuroendocrine tumors (pNETs) are rare, indolent cancers
whose causation is only partly understood. An increasing number of studies have uncovered …